Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.43 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14227481 | 0.90 | KIF11 (0.43) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL16186368 | 0.87 | KIF11 (0.43) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL14226535 | 0.86 | KIF11 (0.40) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL19711845 | 0.86 | KIF11 (0.40) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL16215315 | 0.86 | KIF11 (0.42) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL15744314 | 0.86 | RARB (0.35) | KIF11RARBCYP11B1RARARARG | |
| SCHEMBL15744566 | 0.85 | KIF11 (0.39) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL15744826 | 0.85 | KIF11 (0.39) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL14226537 | 0.85 | KIF11 (0.39) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL15745210 | 0.85 | KIF11 (0.41) | KIF11RARBCYP11B1CYP11B2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120313041-A1 | FOUR-RING COMPOUND HAVING A PLURALITY OF CF2O BONDING GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120313041-A1 | FOUR-RING COMPOUND HAVING A PLURALITY OF CF2O BONDING GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-2123623-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120313041-A1 | FOUR-RING COMPOUND HAVING A PLURALITY OF CF2O BONDING GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, OCIAD1, POU2F2 | KIF11 589/4885RARB 2789/4885CYP11B1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.